N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study

Table 3 Changes in lipoprotein particles after n-3 PUFA administration measured by nuclear magnetic resonance

Lipoprotein particle	Before	After	P-value
VLDL size (nm)	56.3 ± 7.14	45.2 ± 4.01	< 0.001
LDL size (nm)	20.0 ± 0.306	20.1 ± 0.361	0.154
HDL size (nm)	9.13 ± 0.302	9.17 ± 0.382	0.535
Total VLDL & CM concentrations (nmol/L)	73.6 ± 22.0	75.6 ± 38.5	0.850
Large VLDL & CM (nmol/L)	10.4 ± 4.31	2.18 ± 1.81	< 0.001
Medium VLDL (nmol/L)	34.6 ± 11.2	36.5 ± 25.6	0.850
Small VLDL (nmol/L)	28.7 ± 15.3	36.8 ± 20.7	0.380
Total LDL concentration (nmol/L)	1040 ± 237	995 ± 215	0.266
IDL (nmol/L)	158 ± 75.8	155 ± 87.5	0.850
Large LDL (nmol/L)	98.9 ± 145	142 ± 131	0.142
Small LDL (nmol/L)	780 ± 210	698 ± 170	0.151
Total HDL concentration (nmol/L)	34.2 ± 4.42	32.0 ± 5.31	0.110
Large HDL (nmol/L)	6.25 ± 2.14	6.74 ± 3.26	0.531
Medium HDL (nmol/L)	4.73 ± 5.00	3.93 ± 3.60	0.557
Small HDL (nmol/L)	23.2 ± 4.71	21.3 ± 3.42	0.233
LPIR score	65.1 ± 11.1	40.5 ± 14.8	0.001
GlycA	411 ± 50.5	432 ± 49.1	0.129

Data represent the means ± standard deviation. P-values represent differences observed before and after n-3 PUFA administration. VLDL very low-density lipoprotein, LDL low-density lipoprotein, HDL high-density lipoprotein, CM chylomicron, IDL intermediate density lipoprotein, LPIR lipoprotein insulin resistance, GlycA glycoprotein acetylation

ISSN: 1476-511X